Literature DB >> 18674396

Reducing the burden of depression.

Gavin Andrews1.   

Abstract

OBJECTIVE: To consider why the burden of depression persists.
METHOD: The epidemiology and disability associated with depression were reviewed to consider whether depression persists because: the causes are overwhelming, prevention is ineffective, the disease is difficult to detect or diagnose, the condition remits and recurs, treatments do not work, individuals do not seek treatment, or effective care is not provided when they do seek it.
RESULTS: The first 5 possibilities were not considered significant reasons for the persistence of the burden.
CONCLUSION: The burden persists because individuals do not seek treatment for their depression when they relapse and effective proactive treatment is not always provided when they do seek it.

Entities:  

Mesh:

Year:  2008        PMID: 18674396     DOI: 10.1177/070674370805300703

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  7 in total

1.  Pragmatic randomized controlled trial of long-term psychoanalytic psychotherapy for treatment-resistant depression: the Tavistock Adult Depression Study (TADS).

Authors:  Peter Fonagy; Felicitas Rost; Jo-Anne Carlyle; Susan McPherson; Rachel Thomas; R M Pasco Fearon; David Goldberg; David Taylor
Journal:  World Psychiatry       Date:  2015-10       Impact factor: 49.548

2.  Outcome of Psychoanalytic and Cognitive-Behavioural Long-Term Therapy with Chronically Depressed Patients: A Controlled Trial with Preferential and Randomized Allocation.

Authors:  Marianne Leuzinger-Bohleber; Martin Hautzinger; Georg Fiedler; Wolfram Keller; Ulrich Bahrke; Lisa Kallenbach; Johannes Kaufhold; Mareike Ernst; Alexa Negele; Margerete Schoett; Helmut Küchenhoff; Felix Günther; Bernhard Rüger; Manfred Beutel
Journal:  Can J Psychiatry       Date:  2018-11-01       Impact factor: 4.356

3.  Randomised controlled trial of the clinical and cost effectiveness of a specialist team for managing refractory unipolar depressive disorder.

Authors:  Richard Morriss; Sarah Marttunnen; Anne Garland; Neil Nixon; Ruth McDonald; Tim Sweeney; Heather Flambert; Richard Fox; Catherine Kaylor-Hughes; Marilyn James; Min Yang
Journal:  BMC Psychiatry       Date:  2010-11-29       Impact factor: 3.630

4.  Elevated depressive symptoms, antidepressant use, and diabetes in a large multiethnic national sample of postmenopausal women.

Authors:  Yunsheng Ma; Raji Balasubramanian; Sherry L Pagoto; Kristin L Schneider; Annie L Culver; Barbara Olendzki; Lesley Tinker; Simin Liu; Monika Safford; Deidre M Sepavich; Milagros C Rosal; Judith K Ockene; Mercedes Carnethon; Martha Zorn; James R Hébert
Journal:  Diabetes Care       Date:  2011-09-12       Impact factor: 19.112

5.  Tavistock Adult Depression Study (TADS): a randomised controlled trial of psychoanalytic psychotherapy for treatment-resistant/treatment-refractory forms of depression.

Authors:  David Taylor; Jo-anne Carlyle; Susan McPherson; Felicitas Rost; Rachel Thomas; Peter Fonagy
Journal:  BMC Psychiatry       Date:  2012-06-11       Impact factor: 3.630

6.  Self-Management Strategies in Recovery From Mood and Anxiety Disorders.

Authors:  Benjamin Villaggi; Hélène Provencher; Simon Coulombe; Sophie Meunier; Stephanie Radziszewski; Catherine Hudon; Pasquale Roberge; Martin D Provencher; Janie Houle
Journal:  Glob Qual Nurs Res       Date:  2015-09-21

7.  The B-VITAGE trial: a randomized trial of homocysteine lowering treatment of depression in later life.

Authors:  Andrew H Ford; Leon Flicker; Kieran McCaul; Frank van Bockxmeer; Sarah Hegarty; Varsha Hirani; Stephen Fenner; Osvaldo P Almeida
Journal:  Trials       Date:  2010-01-25       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.